Ultragenyx Pharmaceutical Inc. (RARE)
- Sector
- Biotechnology
- Last price
- $17.20
- As of
Kresmion compiles this page from RARE's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Ultragenyx Pharmaceutical Inc. (RARE): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-19.
See the full RARE dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for RARE on one page. Preview it with sample data, then open it live with a free account.
Preview the RARE dossierActive events for RARE
- high13F: funds reduced
3 tracked funds reduced RARE this 2026Q2, institutional consensus
- high13F: large reduction
CITADEL ADVISORS LLC cut 67% of RARE (2026Q2)
- high13F: large reduction
CITADEL ADVISORS LLC cut 87% of RARE (2026Q2)
- high13F: large reduction
MILLENNIUM MANAGEMENT LLC cut 57% of RARE (2026Q2)
- high13F: large increase
TWO SIGMA INVESTMENTS, LP added +64% to RARE (2026Q2)
FREE, NO ACCOUNT
Every event on RARE, as it fires
You are seeing 5 of 10 events recorded on RARE since 2026-06-03.
The five above landed across 2 days. The other 5 were recorded on 2 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in RARE (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| TWO SIGMA INVESTMENTS, LPCUSIP 90400D108 · 2026Q2 | $120.9M | 0.09% | , |
| D. E. Shaw & Co., Inc.CUSIP 90400D108 · 2026Q2 | $57.8M | 0.03% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 90400D108 · 2026Q2 | $25.4M | 0.01% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 90400D108 · 2026Q2 | $13.8M | 0.02% | , |
| CITADEL ADVISORS LLCCUSIP 90400D108 · 2026Q2 | $7M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, RARE
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
RARE against its peers
RARE's operating margin of -79.5% ranks in the 54th percentile of 11 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2026-03-31.
| Metric | RARE | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 673M USD | 110M USD | 88 | 11 |
| Gross margin | n/a | 89.5% | n/a | 5 |
| Operating margin | -79.5% | -85.3% | 54 | 11 |
| Net margin | -85.4% | -109.0% | 50 | 12 |
| Return on equity | n/a | -41.6% | n/a | 14 |
Peers (18): CMPS, NVAX, STOK, IMCR, NBTX, QURE, MESO, URGN, FBRX.D, MAZE, NTLA, ZBIO, MLYS, REPL, ANAB, TYRA, VIR, GHRS. Left out: KLRA (no annual filing), COAG (no annual filing), TRAX (no annual filing), BRVE (no annual filing), GENB (no annual filing), ADRX (no annual filing), KALV.D (no annual filing). Fiscal periods ending between 2025-06-30 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (RARE: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow RARE on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to RARE for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.